Previous 10 | Next 10 |
home / stock / tenx / tenx articles
Once granted, this patent will: provide U.S. intellectual property (IP) protection until December 2040, and may qualify for additional U.S. paten...
Shares of SoFi Technologies, Inc. (NASDAQ: SOFI) fell sharply during Wednesday’s session after Keefe, Bruyette & Woods downgraded rating...
Shares of Icosavax, Inc. (NASDAQ: ICVX) rose sharply in pre-market trading after AstraZeneca announced plans to buy Icosavax in a deal valued at ...
Shares of Beyond Air, Inc. (NASDAQ: XAIR) dipped during Tuesday’s session following weak quarterly results. Beyond Air posted a quarterly lo...
INVO Bioscience, Inc. (NASDAQ: INVO) shares surged in pre-market trading after the company posted a narrower loss for the third quarter. INVO Biosc...
U.S. stocks traded mixed toward the end of trading, with the Dow Jones gaining around 50 points on Monday. The Dow traded up 0.16% to 34,337.33 whi...
Edible Garden AG Incorporated (NASDAQ: EDBL) shares fell on Monday following third-quarter results. Edible Garden posted a quarterly loss of 69 cen...
U.S. stocks traded mostly higher midway through trading, with the Dow Jones gaining around 100 points on Monday. The Dow traded up 0.33% to 34,397 ...
U.S. stocks traded lower this morning, with the Nasdaq Composite falling around 100 points on Monday. Following the market opening Monday, the Dow ...
News, Short Squeeze, Breakout and More Instantly...
Tenax Therapeutics Inc. Company Name:
TENX Stock Symbol:
NASDAQ Market:
Tenax Therapeutics Inc. Website:
Currently Enrolling Patients in Phase 3 LEVEL Study with 24 Investigative Sites Initiated Secured Global Development and Commercial Rights to Levosimendan for Treatment of PH-HFpEF Expanded Intellectual Property Estate for Levosimendan with Issuance of New U.S. Patent ...
Broadens IP protection for oral (TNX-103), IV, and subcutaneous use of levosimendan, and its active metabolites (OR1896 and OR1855), in PH-HFpEF Provides U.S. intellectual property (IP) protection until December 2040, and may qualify for additional U.S. patent term extension (PTE) beyond ...